Price
No data yet.
Social Signal Score
Revenue
$1.55MCompany Profile
- CEO
- Gregg Boehmer
- Sector
- Consumer Cyclical
- Industry
- Auto - Parts
- Employees
- 1
- Beta
- 1.49
- Country
- US
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- -1.48
Financials
Revenue
$1.55M+50359.8%Net Income
$-241.2KEBITDA
$-3.7KFree Cash Flow
$931.9KEPS (diluted)
$-0.00Shares Outstanding (diluted)
3.73B+6936.4%Operating Expenses
$3.7KCash & Debt
$505.00Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2022 | $2.19M | $-1.35M | $-0.00 |
| 2021 | $5.71M | $3.73M | $0.00 |
| 2019 | $1.01M | $-1.20M | $-0.00 |
| 2018 | $91.1K | $-1.32M | $-0.09 |
| 2017 | $24.2K | $-10.0K | $-0.00 |
| 2016 | $30.9K | $-32.9K | $-0.00 |
| 2015 | $43.1K | $-11.1K | $-0.00 |
Valuation
OPTIhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
90+22.73%Social Signal Score
Mentions (3)
- Newsglobenewswire.com·13d ago·Negative
… Canada-Approved Phase 2 MDD Trial and Commercial TRD Supply VANCOUVER, British Columbia, Sept. 23, 2026 (GLOBE NEWSWIRE) -- Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN) ("Optimi" or the "Company"), a commercial-stage pharmaceutical manufacturer of regulated psychedelic drug products, today announced the completion and quality release of a production batch of 5mg naturally derived psilocybin capsules, manufactured end to end at the Company's cGMP facility in Princeton, British Colum…
View source ↗ - Newsglobenewswire.com·14d ago·Negative
Optimi Health Appoints Dr. Michael Blough as Chief Clinical Development Officer VANCOUVER, British Columbia, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN) ("Optimi" or the "Company"), a commercial-stage pharmaceutical manufacturer of regulated psychedelic drug products, today announced the appointment of Michael Blough, Ph.D.
View source ↗ - Newsglobenewswire.com·52d ago·Negative
Optimi Health Establishes Discretionary Equity Facility VANCOUVER, British Columbia, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN) (the “Company” or “Optimi”), a commercial-stage pharmaceutical manufacturer of regulated psychedelic drug products, today announced that it has entered into a common shares purchase agreement (the “Purchase Agreement”) with Seven Knots, LLC (“Seven Knots”), establishing an equity line of credit (the “ELOC”) under which th…
View source ↗
Congress trades
No disclosed congressional trades in OPTI.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.